title: PET/CT: appropriate application in lymphoma.
abstract: Positron emission tomography (PET) integrated with computed tomography (CT) (PET/CT) provides both metabolic and morphologic information, and becomes the most sensitive and specific imaging armamentarium in patients with non-Hodgkin lymphoma (NHL) and HL. This multimodality is being routinely used in staging, response assessment, and end-of-treatment evaluation for most lymphoma subtypes with convincing data. However, there are still controversial issues in the clinical management of patients with lymphoma. This comprehensive review addresses the latest information regarding the appropriate application of Fluorine 18 fluorodeoxyglucose ((18)F-FDG) PET/CT, discusses the current dilemma in the prognostic value of interim PET/CT, and tries to clarify questions existing in PET/CT-navigated application.
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China. xuejuan_wang@hotmail.com.
authors.forename: Xuejuan
authors.initials: X
authors.lastname: Wang
mesh_terms: D019788:Fluorodeoxyglucose F18; D006801:Humans; D008223:Lymphoma / Q000145:classification / Q000000981:diagnostic imaging* / Q000628:therapy; D064847:Multimodal Imaging / Q000379:methods*; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: Positron emission tomography (PET); computed tomography (CT); lymphoma